Welcome To RobinsPost.com

FLYING AROUND THE INTERNET FOR RELATED NEWS VIDEOS.

Related News Videos From Youtube For:

Pracinostat and Acute Myeloid Leukemia - Preliminary Data is Encouraging



Pracinostat is a histone deacetylase (HDAC) inhibitor being developed for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this exclusive interview with Rare Disease Report, Guillermo Garcia-Manero, MD of University of Texas MD Anderson Cancer Center talks about data his group presented at American Society of Hematology (ASH) annual meeting showing the combination of pracinostat plus azacitidine may improve outcomes in older patients with AML. Reference Garcia-Manero G, Atallah, E, Odenike O et al, Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Presented at” American Society Hematology Annual Meeting; December 6-9,2014; SanFrancisco CA. Abstract 947.

Acute Myeloid and Lymphoid Leukemia


Acute Myeloid Leukemia -- Treatment


Immune Based Therapies for MDS and AML


Why curing cancer is so hard | Azra Raza | TEDxNewYork


The AML genome(s): Mutations in four dimensions


Classification and Prognosis in MDS


Facts about myelodysplastic syndrome


Dr. Garcia-Manero on Curing Patients With MDS and AML


Rigosertib in combination with azacitidine: a potential treatment for AML?


What is "MDS"? (Myelodysplastic Syndromes)